BiotechTube
Atamyo Therapeutics

Atamyo Therapeutics

Paris, France· Est.
atamyo.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $48M

Overview

Atamyo Therapeutics is a clinical-stage biotech developing AAV-based gene therapies for rare limb-girdle muscular dystrophies (LGMDs). The company has advanced its lead programs, ATA-100 for LGMD-R9 and ATA-200 for LGMD-R5, into clinical trials, with ATA-100 completing a dose-finding study and ATA-200 having dosed multiple patients. As a private, pre-revenue spin-off from the renowned research institute Genethon, Atamyo combines deep scientific expertise in muscular dystrophy genetics with a focused pipeline targeting high-unmet-need rare diseases.

Neuromuscular DiseasesRare Genetic Disorders

Technology Platform

Optimized AAV (adeno-associated virus) vector-based gene replacement platform, focused on designing tailored delivery systems (serotype, promoter, transgene) for specific muscular dystrophies to enhance safety and efficacy.

Funding History

2
Total raised:$48M
Series A$40M
Seed$8M

Opportunities

The primary opportunity is to deliver the first approved disease-modifying gene therapies for specific LGMD subtypes, addressing a complete unmet need with potential for premium pricing.
Success could validate the platform for expansion into other muscular dystrophies and related cardiomyopathies.
Regulatory designations like the Rare Pediatric Disease Designation for ATA-100 can accelerate development and add significant value.

Risk Factors

Key risks include clinical trial failure or safety issues common to AAV gene therapies, challenges in commercializing an ultra-orphan drug and securing reimbursement, and dependence on raising additional capital as a private, pre-revenue company to fund development through to potential approval.

Competitive Landscape

The competitive landscape for LGMD gene therapy includes other biotechs like Sarepta Therapeutics (with programs for LGMD subtypes) and Pfizer, as well as academic consortia. Competition is emerging but remains fragmented by specific genetic subtypes. Atamyo's deep, focused expertise from Genethon and advanced clinical positioning in LGMD-R5 and R9 provide a competitive edge in these specific niches.

More companies in Cell & Gene Therapy →More companies in France →